TelyRx Holdings (TELY) Investor presentation summary

Business model and market positioning

• Provides direct-to-consumer, vertically integrated digital pharmacy services with a 100% cash-pay model, bypassing insurance complexities and enabling rapid prescription fulfillment and delivery across 48 states.

• Offers access to over 400 generic and branded medications for 60+ conditions, with no single drug accounting for more than 10% of revenue, ensuring diversified sales.

• Targets the fast-growing $98B cash-pay prescription market, which has grown at a 40% CAGR, and is legally protected from competition by major insurance-based pharmacies due to regulatory barriers.

• Operates two licensed pharmacies in Texas and Florida, servicing approximately 97% of the U.S. population, with a monthly shipping capacity of 250,000 prescriptions.

• Emphasizes convenience, transparency, and speed, with prescriptions prescribed, dispensed, and shipped within an hour and free shipping on orders over $100.

Financial performance and growth

• Achieved rapid revenue growth from $9.5M in 2024 to a projected $113M in 2026, with 162% year-over-year growth expected.

• Maintains strong customer retention, with 70% of revenue from repeat customers and a customer lifetime value (LTV) of $504 versus a customer acquisition cost (CAC) of $113, resulting in a 4.5x LTV/CAC ratio.

• Gross profit margins improved from 37% in 2024 to a projected 56% in 2026, with breakeven expected in late 2025 and positive EBITDA in 2026.

• Marketing efficiency is high, with a return on marketing spend ranging from 2.6x to 5.8x and website sessions growing nearly 20x from January 2024 to December 2025.

• Profitable at the second transaction, with a 2.5-month payback period and 47% of new customers converting to repeat customers.

Competitive landscape and differentiation

• Stands out as a fully integrated, cash-pay focused digital pharmacy with a broad offering, while competitors are limited by insurance models or focus on narrow lifestyle categories.

• Regulatory environment creates a defensible moat, as federal law prohibits major insurance-based pharmacies from vertically integrating in the cash-pay segment.

• Balanced customer base by gender and no product concentration risk, with top 10 products accounting for only 31% of revenue.

• In-house marketing and digital-first approach enable rapid optimization and capital-efficient growth.